Isolated, metabolic, and hypertensive gout: a population-based cluster analysis of 94,759 patients
Clicks: 1
ID: 324898
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #174 of 197 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives People with gout exhibit significant clinical heterogeneity due to diverse comorbidity profiles. This study aimed to identify distinct clinical phenotypes using cluster analysis and to evaluate differences in management, specifically urate-lowering therapy (ULT) patterns and sustained serum urate (SU) control. Methods A population-based retrospective cohort study was conducted using the SIDIAP database (Catalonia, Spain), including 94,759 patients with incident gout (2012–2023). A K-prototypes algorithm identified clusters based on demographics and major comorbidities. Outcomes included sustained SU control (defined as SU < 6 mg/dL for ≥80% of the follow-up time) and ULT adherence (Medication Possession Ratio, MPR). Results Three distinct clusters were identified. Cluster 1 (37.0%) was comprised of younger patients (mean age 54) with fewer comorbidities and the highest SU control. Cluster 2 (22.8%) included older patients (mean age 74) characterized by 100% type 2 diabetes prevalence, high obesity (51.3%), and the greatest cardiovascular burden. Cluster 3 (40.2%) featured older patients with hypertension and dyslipidaemia but no diabetes. Overall, management was suboptimal in all groups; only 12% of patients achieved sustained SU control. While Cluster 2 had higher ULT prescription rates, Cluster 1 showed better adherence and SU control. Conclusion Gout manifests in three clearly differentiated clinical phenotypes, each potentially reflecting a distinct predominant aetiology of hyperuricaemia (isolated/genetic, insulin-resistance-mediated, or renal-vascular). The identification of these high-risk metabolic and hypertensive clusters underscores the need for comorbidity-driven management and tailored therapeutic strategies.
| Reference Key |
openalex_W7202394825
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Maria Antònia Pou, Daniel Martínez-Laguna, Carlen Reyes, Pau Satorra, Cristian Tebé, Hèctor Corominas, Nicola Dalbeth, Cèsar Díaz‐Torné |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag415
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.